Live Breaking News & Updates on Jan Swastya Abhyan

Stay updated with breaking news from Jan swastya abhyan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Covid-19: Why is there a shortage of Remdesivir?- Business News


Inside Remdesivir puzzle: 6 producers, little supply!
Demand fell to almost nil by January after the first wave of the pandemic in the country. Since there was no demand, most manufacturers stopped giving fresh orders for manufacturing
PB Jayakumar | May 3, 2021 | Updated 19:22 IST
Demand for Remdesivir fell to almost nil by January after the first wave of the pandemic in the country
Reduction in production due to less demand after the first wave of coronavirus and lack of vigil on the part of the Government to ensure stockpiling led to current Remdesivir crisis, say sources.
Gilead Life Sciences, the innovator of the re-purposed drug, had licensed six manufacturers in India to produce the drug. Most of them were dependent on contract manufacturers and their subsidiaries to make the product. Demand fell to almost nil by January after the first wave of the pandemic in the country. Since there was no demand, most manufacturers stopped giving fresh orders for ma ....

United States , Daarab Patel , Jan Swastya Abhyan , Gopakumarg Nair , Zydus Cadila , Teva Pharma , National Pharmaceutical Pricing Authority , Department Of Revenue On , Supreme Court , Indian Drug Manufacturers Association , Dr Reddy Labs , Gilead Sciences United States , Supreme Court On , Gilead Life Sciences , Life Sciences , Hetero Drugs , Jubilant Ingrevia , Secretary General , Indian Drug Manufacturers , Egyptian Pharma , Patents Act , Patent Act , Emdesivir Demand , Remdesivir Shortage , Emdesivir Shortage India , Covid 19 Remdesivir ,

Covid-19: Why is there a shortage of Remdesivir?


Covid-19: Why is there a shortage of Remdesivir?
PB Jayakumar
© India Today Group
Covid-19: Why is there a shortage of Remdesivir?
Reduction in production due to less demand after the first wave of coronavirus and lack of vigil on the part of the Government to ensure stockpiling led to current Remdesivir crisis, say sources.
Gilead Life Sciences, the innovator of the re-purposed drug, had licensed six manufacturers in India to produce the drug.  Most of them were dependent on contract manufacturers and their subsidiaries to make the product. Demand fell to almost nil by January after the first wave of the pandemic in the country. Since  there was no demand, most manufacturers stopped giving fresh orders for manufacturing. Neither the manufacturers nor the policy makers anticipated a second wave and failed to stockpile the life saving drug, sources said. ....

United States , Daarab Patel , Jan Swastya Abhyan , Gopakumarg Nair , Zydus Cadila , Teva Pharma , National Pharmaceutical Pricing Authority , India Today Group Covid , Department Of Revenue On , Supreme Court , Indian Drug Manufacturers Association , Dr Reddy Labs , Gilead Sciences United States , Supreme Court On , Gilead Life Sciences , India Today Group , Life Sciences , Hetero Drugs , Jubilant Ingrevia , Secretary General , Indian Drug Manufacturers , Egyptian Pharma , Patents Act , Patent Act , ஒன்றுபட்டது மாநிலங்களில் , ஜய்துச் காடிலா ,